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Mutation 677 C to T in the methylenetetrahydrofolate reductase gene
aggravates hyperhomocysteinemia in hemodialysis patients. Hyperhomo-
cysteinemia is frequent in hemodialysis patients and represents an inde-
pendent risk factor for vascular disease in these patients. Elevated total
homocysteine (tHey) plasma levels can result from defective remethyla-
tion of Hey to methionine due to decreased activity of the enzyme
methylenetetrahydrofolate reductase (MTHFR). A genetic aberration in
the MTHFR gene (677 C to T substitution) has been shown to result in
reduced MTHFR activity. We tested the hypothesis that elevation of tHey
plasma levels in hemodialysis patients is influenced by the 677 C to T
mutation of the MTHFR gene and examined the relation of the genotype
with tHey, folate and vitamin B12 plasma levels in these patients. The
allelic frequency of the MTHFR mutation was evaluated in 203 patients
maintained on chronic hemodialysis treatment. Total Hey, folate, vitamin
B12 levels and the MTHFR mutation were analyzed in 69 of the 203
patients and in 69 age- and sex-matched healthy control subjects. The
allelic frequency of the 677 C to T transition in the MTHFR gene in
hemodialysis patients was 34.7% versus 35.5% in healthy controls, Of 203
patients 26 (12.8%) were homozygous for the mutation (+1+) versus
10.2% in healthy subjects. The heterozygous (+1—) genotype was identi-
fled in 43.8% of patients versus 50.7% in controls. The mean tHey level in
hemodialysis patients was 28.7 11.0 j.mol/liter versus 10.0 3.0
.tmo1Iliter in control subjects. The mean tHey levels were 36.4 13.4
j.mol/Iiter in (+1+) patients and 12.2 4.5 .rmol/liter in (+1+) controls,
28.7 10.8 mol/liter in (+1—) patients and 9.9 2.7 jmol/liter in (+1—)
controls and 25.4 8.5 mol/liter in (—I—) hemodialysis patients versus
9.7 2.8 itmol/liter in (—I---) controls. There was no significant difference
of folate and vitamin B12 concentrations in patients and controls with
different MTHFR genotypes. Analysis of covariance including age, gen-
der, folate concentrations, vitamin B12 levels, albumin and creatinine as
covariables revealed a significant influence of the (+1+) genotype, albu-
min and folate status on tHey levels in hemodialysis patients. Together,
our data demonstrate that the extent of hyperhomocysteinemia in hemo-
dialysis patients is not only the result of uremia or folate status, but is also
genetically determined by the (+1+) MTHFR genotype. The presence of
the 677 C to T mutation in the MTHFR gene does not appear to represent
a risk factor for development of end-stage renal disease.
Homocysteine (Hey), a sulfur containing amino acid, is the
demethylated derivate of the essential amino acid methionine and
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is formed during protein metabolism by the adenosylmethionine-
dependent conversion of methionine to cysteine [1]. Low intra-
cellular concentrations of this potentially cytotoxic sulfur amino
acid are maintained by remethylation to methionine or transsul-
furation to cysteine. During transsulfuration the enzyme cystathi-
onine--synthase (CBS) catalyzes the irreversibel condensation of
Hey and serine to cystathionine, using vitamin B6 as a cofactor,
and contributes to the maintenance of normal postprandial Hey
concentrations [2]. Remethylation to methionine can be accom-
plished by two pathways. In one pathway, the methyl donor for the
conversion of Hey to methionine is provided by the reduction of
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate by
the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR).
5-methyltetrahydrofolate, the active form of folate, then acts as
the methyl donor for the vitamin B12 dependent remethylation of
Hey to methionine by the enzyme 5-methyltetrahydrofolate-ho-
moeysteine methyltransferase (methionine synthetase). Alterna-
tively, betaine can serve as methyl donor to allow formation of
methionine by the enzyme betaine-homocysteine methyltrans-
ferase. The remethylation enzymes serve to maintain normal
fasting Hey concentrations [2].
Hyperhomocysteinemia can be classified into moderate, inter-
mediate and severe forms that are defined as basal plasma Hey
concentrations between 16 and 30, between 31 and 100, and above
100 nmol/ml, respectively [3]. Elevated Hey levels have been
reported to be associated with an increased risk for cerebrovas-
cular, peripheral vascular, coronary artery disease and for deep
vein thrombosis in patients without renal failure [4—61. In end-
stage renal disease patients who are on maintenance hemodialy-
sis, increased plasma Hey concentrations are common and have
been shown to represent an independent risk factor for vascular
disease [7—161.
The adverse vascular effects of Hey leading to atherothrombosis
have been intensively studied. In animals, administration of Hey
thiolactone caused patchy desquamation of the vascular endothe-
hum, followed by increased platelet consumption and thrombosis
[17, 18]. The endothelial toxicity of Hey is attributed to the
sulthydiyl group that generates hydrogen peroxides, raising the
possibility of an involvement of free radicals [19]. It has been
shown that short-term exposition of endothelial cells (EC) to Hey
stimulates the production of nitric oxide, which is able to protect
EC from Hey-induced injury by formation of S-nitrosothiol [20,
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21]. With prolonged Hey exposure, however, the protective mech-
anism is lost because of toxic effects of Hey generated hydrogen
peroxides. Consequently, accumulation of platelets occurs at the
sites of vascular injury. Further mechanisms that are supposed to
underly the accelerated atherogenesis in homocysteinemia are the
interference with natural anticoagulants and the fibrinolytic sys-
tem [22, 23], the initiation of vascular smooth muscle cell prolif-
eration [24], and oxidation of low-density lipoproteins [25].
Elevated plasma Hey levels can result from genetic defects of
enzymes, necessary for either remethylation or transsulfuration of
Hey, such as severe MTHFR deficiency [26], inherited thermo-
lability of MTHFR [27] and CBS deficiency [1] or nongenetic,
acquired factors, such as vitamin B12 [28], vitamin B6 [29] and
folate deficiency [30], and can be lowered by vitamin intervention
therapy [31].
Recently, a C to T mutation at nucleotide position 677 of the
MTHFR coding sequence leading to an exchange of a highly
conserved alanine to a valine residue was identified [32]. The
allelic frequency of this substitution was 38% in 57 French
Canadian individuals without renal disease. The presence of the
mutation was shown to correlate with a reduced specific MTHFR
activity and increased enzyme thermolability in lymphocyte ex-
tracts. Furthermore, homozygous individuals had significantly
elevated plasma total Hey (tHey) levels, almost twice the values
obtained in heterozygotes and non-carriers. The tHey concentra-
tions in heterozygous subjects and individuals without mutation
were indistinguishable.
The allelic frequency of the 677 C to T MTHFR mutation and
the impact of the mutation on hyperhomocysteinemia in hemodi-
alysis patients is unknown. To investigate the hypothesis that tHey
plasma levels in these patients are influenced by the presence of
the MTHFR mutation, we evaluated the frequency of the
MTHFR gene defect in a cohort of 203 patients on maintenance
hemodialysis, and examined whether or not the genotype is
related to tHey, folate and vitamin B12 levels in a large subset of
these patients.
METHODS
Study population
To determine the allelic frequency of the 677 C to T transition
in the MTHFR gene, 203 patients maintained on chronic hemo-
dialysis treatment at the three dialysis units of the University
Hospital of Vienna from December 1994 to July 1996 were
investigated. The mean age of the patients (88 females, 115 males)
was 56.9 15.5 years. Dialysis treatment was initiated because of
end-stage renal disease due to secondary kidney graft failure (N =
41), shrunken kidneys of unknown etiology (N = 40), glomerulo-
nephritis (N = 31), diabetic nephropathy (N = 26), chronic
interstitial nephritis (N = 15), urogenital malformations or ma-
lignancies (N = 14), polycystic kidney disease (N = 13), analgesic
nephropathy (N = 10), nephrosclerosis (N = 8), and miscella-
neous nephropathies (N = 5). The mean duration of hemodialysis
treatment was 2.2 2.4 years. All patients received a vitamin
supplementation including 0.16mg of folate and 10mg of vitamin
B6 daily.
To find out whether tHey plasma levels are influenced by the
C677T mutation in the MTHFR gene, the MTHFR genotype,
plasma tHey, folate and vitamin B12 concentrations, creatinine
and albumin levels were analyzed in 69 of the 203 hemodialysis
patients (29 females, 40 men, mean age 54.4 15.5 years), who
were on dialysis treatment at one of the three dialysis units.
Sixty-nine age- and sex-matched healthy subjects without renal
disease or clinical signs of coronary artery disease, cerebrovascu-
lar or peripheral vascular disorders served as controls.
Biochemical assays
Citrated blood was collected after an overnight fast from 69
hemodialysis patients of one dialysis unit prior to dialysis and
from the 69 age- and sex-adjusted controls. Samples were imme-
diately placed on ice and centrifuged within 30 minutes at 2000 g
at 4°C (20 mm). Plasma aliquots were stored at —70°C.
Total (that is, free plus protein-bound) plasma Hey concentra-
tions were determined by automated high-performance liquid
chromatography (HPLC) with reverse-phase separation and flu-
orescent detection using a commercially available kit (Immundi-
agnostik, Bensheim, Germany) according to the method originally
described by Araki and Sako [33]. Hyperhomocysteinemia was
defined as tHey levels above 15 tmo1/liter. This cut off was
determined from the mean tHey level (9.7 2.8 .rmol/liter) plus
2 SDS in control subjects who were negative for the 677 C to T
mutation in the MTHFR gene.
Plasma folate (5-methyltetrahydrofolate) and vitamin B12 levels
were measured with a radioassay, which allowed simultanous
determination of both vitamin concentrations in a single reaction
tube (SimuITRAC-SNB; Becton Dickinson, Ontario, Canada).
Folate deficiency was defined as plasma concentration of less than
3.4 nmol/liter. Vitamin B12 deficiency was defined as a concentra-
tion of less than 118 pmollliter, respectively.
PCR analysis of MTHFR gene
Identification of the 677 C to T transition in the MTHFR gene
was performed as previously described [32]. In brief, 500 .d of
citrated blood was frozen twice at —70°C. Cellular DNA was
obtained by thawing and boiling for 10 minutes, followed by
centrifugation at 12,000 g (10 mm). The supernatants were
collected and 5 jd of a 1:10 dilution were used in a 50 p.1 PCR
reaction containing 10 mM Tris-HC1 (pH 8.8), 50 mM KC1, 0.1%
Triton X-100, 1.25 mrvi MgCl2, 0.2 m of each nucleoside triphos-
phate, 30 pmol of each primer and 1.25 units of AmpliTaq DNA
Polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). PCR was
performed using the primers described by Frosst et al: 5'-
TGAAGGAGAAGGTGTCTGCGGGA-3' and 5'-AGGACG-
GTGCGGTGAGAGTG-3' [32]. Thermocycling conditions con-
sisted of 40 cycles of denaturation at 95°C for one minute,
annealing at 60°C for one minute and extension at 72°C for one
minute, preceded by an initial denaturation step at 95°C for three
minutes and followed by a terminal extension of five minutes at
72°C. Two microliters of the 198-bp PCR product were subjected
to Hinf I digestion (0.5 units enzyme in a 20 p.1 digest). The
presence of a mutation creates a Hinf 1 recognition sequence that
leads to a digestion of the 198 bp PCR product into fragments of
175 bp and 23 bp, respectively. Heterozygous subjects show three
fragments (198 bp, 175 bp and 23 bp), and a homozygous C to T
substitution results in the production of two fragments of 175 bp
and 23 bp. Hinf I digests of PCR amplification products were
analyzed by electrophoresis through 6% polyacrylamide gels
(Novex, San Diego, CA, USA) followed by ethidium bromide
staining.
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Table 1. Genotype and allelic frequency of the (C677T) MTHFR
mutation in hemodialysis patients and control subjects
MTHFR (C677T)
Hemodialysis
patients
Hemodialysis
patients
Control
subjects
genotype N = 203 N = 69 N = 69
(+1+) 26 (12.8%)
(+1—) 89 (43.8%)
(—I--) 88 (43.4%)
Allelic frequency 34.7%
12(17.4%) 7 (10.2%)
29 (42.0%) 35 (50.7%)
28 (40.6%) 27 (39.1%)
38.4% 35.5%
There was no significant difference of the MTHFR (C677T) genotype or
allelic frequency between hemodialysis patients (N = 203), control
subjects (N = 69) and the subgroup of hemodialysis patients (N = 69) in
whom tHcy plasma levels were determined.
Statistical analyses
Comparison of the frequency of the different MTHFR geno-
types in hemodialysis patients and the control group was per-
formed by chi square test. For analysis of covariance, tHcy plasma
levels were transformed (natural logarithm, In). Descriptive sta-
tistics included means SD, geometric means, medians, full
ranges and 10th to 90th percentile ranges.
Separate comparisons of the tHcy plasma levels between the
three groups of (—I---) subjects with (+1—) and (+1+) subjects
were performed by analysis of covariance in both the patient and
the control group. The covariables were folate, vitamin B12, age,
gender, albumin and creatinine for hemodialysis patients, and
folate, vitamin B12, age and gender for healthy subjects. For
assessment of the interaction of suboptimal folate status and
MTHFR genotype on tHcy plasma levels, a less than median
plasma folate (yes/no) term was included as covariable. Individual
comparisons between the groups were conducted by post hoc
analysis (Scheffe's test). All calculations were performed by the
statistical software package SAS (SAS Institute Inc., Cary, NC,
USA).
RESULTS
MTHFR genotype
The allelic frequency of the 677 C to T transition in the
MTHFR gene in hemodialysis patients was 34.7% versus 35.5% in
healthy controls. Twenty-six of 203 patients (12.8%) showed a
homozygous (+1+) mutation versus 7 of 69 healthy subjects
(10.2%). The heterozygous (+/—) transition was identified in 89
of 203 patients (43.8%) versus 35 of 69 controls (50.7%). The
mutation was not present in 88 of 203 (—/—) patients (43.4%) and
in 27 of 69 (—/--) control subjects (39.1%). In the 69 hemodialysis
patients of one hemodialysis unit in whom tHcy plasma levels had
been analyzed, the (+/+) genotype was identified in 12 of 69
patients (17.4%), which was not significantly different compared
with the prevalence of 12.8% of the whole study population of 203
patients. In 29 of these 69 hemodialysis patients the (+/—)
genotype was found (42.0%), and 28 of 69 patients (40.6%) were
negative for the MTHFR mutation (Table 1).
Total plasma homocysteine levels
The MTHFR genotype, fasting tHcy levels, folate and vitamin
B12 concentrations were determined in 69 hemodialysis patients
and in 69 age- and sex-matched control subjects. The mean tHcy
level in hemodialysis patients was 28.7 11.0 j.mol/liter versus
10.0 3.0 ,u.mol/liter in control subjects. In (+1+) patients the
mean tHcy level was 36.4 13.4 j.tmol/liter and 12.2 4.5
j.Lmol/liter in (+/+) controls. In (+/—) patients the mean tHcy
concentration was 28.7 10.8 j.Lmol/liter versus 9.9 2.7
/Lmol/liter in (+/—) controls, and in (—I—) hemodialysis patients
the mean tHcy level was 25.4 8.5 imol/liter versus 9.7 2.8
j.tmol/liter in (—/—-) controls (Fig. 1). Only 5 of 69 patients (7.3%)
had tHcy levels below the cut off point of 15 j.Lmol/liter, in contrast
to 63 of 69 healthy subjects (91.3%). None of these 5 patients was
homozygous for the MTHFR gene variation [2 patients were
(+/—) and 3 patients (—/--), respectively], whereas in the control
group 5 of 63 (7.9%) subjects with tHcy levels < 15 .tmol/liter
were identified as homozygous carriers of the MTHFR mutation.
There was a significant influence of folate and serum albumin
levels on tHcy levels in hemodialysis patients (F test, P = 0.039
and P = 0.041). Post hoc analysis revealed a significant influence
of the (+1+) C677T MTHFR-gene mutation on tllcy plasma
levels compared with non-carriers (Scheffe's test, P < 0.05). The
geometric mean tHcy level in (+1+) patients was 27.4% higher
than tHcy level of the (+/—) patients and 41.3% higher than in
patients without mutation (Table 2). An increase of serum
albumin levels of 1 g/liter resulted in an estimated increase of ln
tHcy plasma levels of 0.027 mol/liter. The other covariables
(vitamin B12, creatinine, age and sex) had no significant influence
on tHcy levels.
If a 'folate below/above median' term was included, a significant
influence of low folate levels ( sample median of 23.1 nmol/liter)
on tHcy levels was obtained in all 69 hemodialysis patients (F test,
P = 0.049). Post hoc analysis in this model again showed a
significant influence of the (+/+) MTHFR genotype on tHcy
plasma levels compared with (—I—) patients (Scheffe's test, P <
0.05).
Separate analysis of patients with folate levels below the sample
median (N = 34) revealed a significant trend for an influence of
the MTHFR genotype on tHcy plasma levels (F* test, P = 0.07;
Scheffe's test for comparison of (+/+) versus (—/—) genotype,
P < 0.05). There was no influence of the MTHFR genotype on
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Fig. 1. Plasma tHey levels (mean SD) in 69 hemodialysis patients (LI)
and 69 age- and sex-matched healthy subjects () with different MTHFR
genotypes. *p < 0.05, for comparison of (+1+) versus (—I—) hemodialysis
patients.
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Table 2. MTHFR (C677T) genotype, tHcy, folate and vitamin B12 plasma levels in 69 hemodialysis patients and 69 age- and sex-matched controls
MTHFR Number of
genotype subjects mean so
Geometric
mean Median Range
10th 90th
Percentile Percentile
tHcy plasma levels pmol/Iiter
(+1+) 12(7) 36.4 13.4 (12.2 4.5) 33.9(11.4) 35.0 (14.4) 45.2(11.1) 16.3 (6.8) 52.4 (17.9)
(+1—) 29 (35) 28.7 10.8 (9.9 2.7) 26.6 (9.5) 27.2 (9.7) 49.6 (10.1) 11.6 (6.3) 43.4 (13.6)
(—I-—) 28 (27) 25.4 8.5 (9.7 2.8) 24.0 (9.3) 24.4 (8.9) 32.9 (9.5) 15.3 (6.8) 37.7 (14.9)
Total 69(69) 28.7 11.0 (10.0 3.0) 26.6 (9.6) 27.6 (9.4) 50.0 (12.3) 15.3 (6.8) 44.3 (14.9)
Folate plasma levels nmol/liter
(+1+) 12 (7) 25.1 16.7 (14.2 7.0 22.1 (12.8) 22.6 (12.2) 63.7 (19.4) 12.4 (6.2) 27.9 (25.6)
(+1—) 29 (35) 26.1 15.8 (15.5 6.2) 22.8 (14.5) 23.0 (13.3) 73.4 (25.7) 13.0 (10.5) 46.9 (26.2)
(—7—) 28(27) 27.7 12.5 (18.8 7.9) 25.2 (17.5) 25.6 (15.3) 48.2 (29.7) 15.1 (11.5) 47.8 (33.2)
Total 69 (69) 26.6 14.6 (16.7 7.1) 23.6 (15.4) 23.1 (14.2) 73.4 (33.1) 13.6 (10.0) 46.9 (27.4)
Vitamin B12 plasma levels pmol/liter
(+1+) 12 (7) 230.5 103.5 (174,5 72.1) 213.3 (162.5) 208.2 (150.6) 366.2 (220.6) 140.1 (86.4) 344.8 (307.0)
(+7—) 29 (35) 293.0 157.5 (235.2 104.0) 255.1 (216.3) 253.3 (222.0) 509.5 (508.3) 114.3 (121.3) 571.2 (350.0)
(—I---) 28 (27) 280.1 134.6 (223.0 86.6) 252.4 (208.2) 250.3 (209.8) 518.8 (404.5) 135.0 (135.3) 491.7 (354.0)
Total 69 (69) 276.9 140.2 (224.2 95.1) 246.2 (207.0) 242.8 (209.8) 524.4 (528.7) 126.6 (122.0) 491.7 (350.0)
Data are presented as hemodialysis patients' (control) levels.
tHcy levels in 35 patients with folate levels above the sample
median (F-test, P = 0.43; Scheffe's test, NS).
In healthy subjects there was a slight, but not significant
difference in tHey plasma levels between the three groups with
different MTHFR genotypes (F test, P = 0.29; Scheffe's test, NS).
Folate concentration, age and sex had a significant influence on
tHcy level (F test, P = 0.029, P = 0.039 and P = 0.003,
respectively). An increase of age of one year resulted in an
estimated increase of the In tHey plasma level of 0.004 .tmol/liter.
In male subjects the estimated elevation of the natural logarithm
(in) tHcy plasma level was 0.204 .rmol/liter compared with female
subjects. No influence of the vitamin B12 concentration on tHcy
plasma levels was detectable. Inclusion of a 'folate below/above
median' term revealed a significant influence of folate levels
below the sample median (< 14.2 nmol/liter) on tHcy plasma
levels (F test, P = 0.040).
Separate analysis of healthy subjects with folate levels below the
sample median (N = 34) revealed no influence of the MTHFR
genotype on tHcy plasma levels [F* test, P = 0.12; Scheffe's test
for comparison of (+1+) versus (—I—) genotypes, NS]. No
influence of the MTHFR genotype on tllcy levels in 35 healthy
subjects with folate levels above the sample median was observed
(F-test, P = 0.29; Scheffe's test, NS). In this model, age was the
only covariable with significant influence on tHcy levels (F-test,
P = 0.0061) if high folate levels were present. Geometric and
arithmetic means of tHcy levels in healthy subjects are depicted in
Table 2.
Vitamin concentrations
The mean folate concentration was 26.6 14.6 nmol/liter
(normal range 3.4 to 38 nmol/liter) in hemodialysis patients versus
16.7 7.1 nmol/liter in controls. In (+1+) patients the mean
folate level was 25.1 16.7 nmol/liter and 14.2 7.0 nmoi/liter in
(+1+) controls. In (+1—) patients the mean folate concentration
was 26.1 15.8 nmol/liter and 15.5 6.2 nmol/liter in (+/—)
controls, and in (—I—-) dialysis patients the mean folate level was
27.7 12.5 nmol/liter and 18.8 7.9 nmol/liter in (—I—)controls.
The mean vitamin B12 concentration was 276.9 140.2 pmol/liter
in the patient group (normal range 118 to 720 pmol/Iiter) and
224.2 95.1 pmol/liter in healthy subjects. The mean B12 level in
(+1+) patients was 230.5 103.5 pmol/liter and 174.5 72.1
pmol/liter in (+/+) controls. In (+7—) patients the mean B12
concentration was 293.0 157.5 pmol/liter and 235.2 104.0
pniol/liter in (+7—) controls, and in (—I—) patients the mean B12
level was 280.1 134.6 pmol/liter and 223.0 86.6 pmol/liter in
(—I—) controls. The folate and vitamin B12 concentrations did not
differ significantly between the different MTHFR genotypes in the
patient and the control groups. The mean vitamin and tHcy levels
of the patients and the controls with different MTHFR genotypes
are summarized in Table 2.
Not one of the patients or the healthy controls had a folate
deficiency. Deficiency of vitamin B12 was identified in 4 of 69
patients (5.8%) and in 4 of 69 control subjects (5.8%). The mean
vitamin B12 level in B12 deficient patients was 111.1 3.2
pmol/liter and 96.0 14.8 pmol/liter in B12 deficient control
subjects. The mean tHcy level in this patient group was 37.3
15.7 .tmol/ljter and 11.6 2.5 j.mol/liter in the control individu-
als. One patient and one control showed the wild-type MTHFR
genotype. Three patients and two controls were identified as
heterozygous carriers and one control had a homozygous C677T
mutation in the MTHFR gene.
DISCUSSION
The present study provides evidence that the extent of hyper-
homocysteinemia in hemodialysis patients is not only due to the
impairment of renal function or folate status, but is also geneti-
cally determined. We demonstrate that tHey plasma levels in
these patients are influenced by a genetic defect localized in the
MTHFR gene. In patients with a homozygous 677 C to T MTHFR
mutation the mean tHcy plasma level was 36.4 13.4 mol/liter,
which was significantly higher compared to tHcy concentrations of
patients without mutation (25.4 8.5 mol/1iter), and was about
thrice the mean normal value of 9.7 2.8 mol/liter of the age-
and sex-matched healthy (—I—) subjects.
In the 406 chromosomes of our 203 hemodialysis patients we
found an allelic frequency of 34.7% for the 677 C to T transition
in the MTHFR gene that was almost identical with the frequency
of 35.5% in the control group. The frequency of the homozygous
mutation in this Austrian cohort of hemodialysis patients was
12.8%, which corresponds with the frequency described in a mixed
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population of patients who were either maintained on peritoneal
or hemodialysis treatment [34]. The frequency of 10.2% in the
healthy (+1+) control subjects is in line with the observation in
Canadian individuals and in populations of European, Middle
Eastern and Japanese origin [32, 35, 36]. In contrast, the fre-
quency described in Finnish (5.4%), Dutch (5.2%) and African
American (1.4%) population groups was significantly lower [35,
37], suggesting ethnic variations.
The enzyme MTHFR represents an important cofactor in-
volved in the Hcy remethylation pathway. Decreased MTHFR
activity results in inadequate production of 5-methyltetrahydrofo-
late, required for the remethylation of Hcy to methionine, with
the consequence of elevated plasma Hcy concentrations [26, 27].
Frosst and collegues [32] recently demonstrated that the homozy-
gous and the heterozygous 677 C to T mutation in the MTHFR
gene represent the causative genetic defect associated with a
thermolabile MTHFR phenotype originally described by Kang
and co-workers [27]. The thermolabile mutant leads to elevated
Hcy levels due to decreased MTHFR activity. In homozygous
subjects the presence of mutant MTHFR was associated with
elevated tHcy levels of 22.4 2.9 molIliter that were almost
twice the values for (—I---) individuals [32]. Homocysteine con-
centrations did not differ between heterozygotes and non-carriers.
In our control group the mean tHcy plasma level in (+1+)
subjects was 12.2 4.5 /Lmol/liter, which did not differ signifi-
cantly from the tHcy levels of (+1—) or (—I—) individuals. Folate
status, age and sex significantly influenced tHcy levels, whereas
the MTHFR genotype had no influence even in healthy subjects
with folate levels below the sample median.
Hyperhomocysteinemia is a well established independent risk
factor for development of vascular disease [4—6]. Elevated Hcy
concentrations resulting from the homozygous thermolabile
MTHFR mutant have been shown to be associated with coronary
artery disease, myocardial infarction, cerebral artery disease,
peripheral artery disease and venous or arterial thrombosis in
individuals without renal failure [37—41]. This was initially diag-
nosed by biochemical methods [38, 39] and recently on the basis
of molecular genetic analysis [37, 40, 41]. Atherothrombotic
complications are the leading cause of death in maintenance
hemodialysis patients [42, 43]. The age-specific cardiovascular
disease risk of mortality is at least 3.5 to 10 times higher in the
dialysis population than among individuals without dialysis treat-
ment [44—46]. However, atherothrombotic cardiovascular disease
in end-stage renal disease patients cannot be completely ex-
plained by conventional risk factors such as hypertension, hyper-
cholesterolemia, obesitas, age and smoking. Hyperhomocysteine-
mia is commonly observed in end-stage renal disease. It was first
reported in hemodialysis patients in 1980 by Wilcken, Gupta and
Reddy [7] and later confirmed by other groups [8—15]. Elevated
Hcy levels in hemodialysis patients have been shown to be
associated with an increased frequency of atherosclerotic vascular
disease [11, 13—16]. In our study the mean plasma tHcy concen-
tration in predialysis probes of chronic hemodialysis patients was
28.7 11.0 molJliter, which is similar to the tHcy levels reported
previously [10, 12, 13, 15, 16, 47].
The pathogenesis leading to elevated Hcy concentrations in
hemodialysis patients is currently unclear. Increased Hcy concen-
trations are already found at the incipient stage of chronic renal
failure, and hyperhomocysteinemia progresses in parallel with the
decline of renal function [7, 10, 11, 48—50]. There is evidence in
the literature that the kidney may play a substantial role in Hcy
metabolism. About 30% of plasma Hcy is not protein-bound (free
fraction, consisting of a mixture of cysteine-Hcy, Hcy and homo-
cystine) and can freely pass the glomerular basement membrane
with a daily filtration rate of about 550 mol [51, 52]. More than
99.5% of Hcy is reabsorbed from the ultrafiltrate by the renal
tubule and is suggested to be converted into metabolites of the
transsulfuration pathway (mainly cystathionine), as was demon-
strated in isolated rat renal cortical tubules [53]. Alternatively,
remethylation by the enzyme betaine-Hcy methyltransferase [54]
or 5-methyltetrahydrofolate-Hcy methyltransferase [55], which
have been identified in human kidneys, might be involved. Based
on the assumption that the human kidney might be important for
Hcy metabolism it was speculated that in the case of decreased
glomerular filtration, Hcy might not reach the renal metabolic
site, the tubule cell, and may not be degraded because of tubular
cell dysfunction in end-stage renal disease. Uremic toxins may
also contribute to hyperhomocysteinemia by inhibition of Hcy
metabolism in various organs [56]. However, a recent study by
Perna and collegues [57] suggests that the high Hcy concentra-
tions found in uremia result in accumulation of highly toxic
intracellular S-adenosyl-Hcy, an inhibitor of methyltransferases
that is normally eliminated by hydrolysis to Hcy.
It is well established that plasma Hcy levels are also influenced
by the nutritional status and renal function. In our study, albumin
levels had a significant influence on tHcy plasma levels in hemo-
dialysis patients. This observation is in line with the findings of
Hultberg, Andersson and Sterner in chronic renal failure patients
[10]. In contrast to Bostom and co-workers, who studied a dialysis
patient group consisting of hemodialysis and peritoneal dialysis
patients [58}, we did not find a significant interaction of serum
creatinine with tHcy levels in our patient population. It has been
shown that plasma tHcy concentrations are amplified by low
serum folate and vitamin B12 levels [28, 30], and even marginal
deficiency of folate can result in moderate hyperhomocysteinemia
[30, 58, 59]. In our study folate and vitamin B12 levels were
generally higher in hemodialysis patients than in controls probably
due to supplementation of 0.16 mg of daily folate and nutritional
factors. In homozygous patients the mean folate concentration
was 25.1 16.7 nmol/liter, which is within the upper normal
range. The mean vitamin B12 level of 230.5 103.5 pmol/liter in
homozygous hemodialysis patients was clearly above the lower
normal value of 118 pmollliter. Therefore, we can exclude vitamin
B12 and folate deficiency as a cause of high tHcy levels in
homozygous dialysis patients. In heterozygous individuals and in
subjects with the wild-type MTHFR genotype, vitamin B12 defi-
ciency was identified in 5.8% of patients showing a mean tHcy
level of 37.3 15.7 imol!liter and in 5.8% of the control group
exhibiting a mean tHcy level of 11.6 2.5 tmol/liter. These data
suggest a trend to higher tHcy concentrations in B12 deficient
hemodialysis patients and in healthy individuals.
Recent studies suggest that the homozygous carrier status for
the 677 C to T MTHFR mutation only affects tHcy plasma levels,
if suboptimal folate concentrations are present [59, 60]. In ho-
mozygous subjects without renal failure fasting tHcy concentra-
tions were 24% greater among individuals with plasma folate
concentration below the sample median (< 15.4 nmol!liter) than
in subjects without mutation [60]. No difference in Hcy levels was
observed between genotypes in individuals with folate levels >
15.4 nmol/liter. Similar observations have been described in
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patients with myocardial infarction [36] and in a mixed population
of dialysis patients who were either on peritoneal or hemodialysis
treatment [58]. In the present study we found no significant
influence of the (+1+) MTHFR genotype on tHcy levels in the
control subjects whether or not suboptimal folate concentrations
(<sample median of 14.2 nmollliter) were present. In contrast, in
hemodialysis patients a significant influence of homozygosity for
the MTHFR polymorphism on tHcy plasma levels was present if
folate levels were below the sample median.
Numerous investigators have demonstrated that plasma Hcy
levels can be lowered by vitamin intervention therapy in patients
with and without renal failure [12, 31, 47, 61—63]. Bostom and
collegues observed a trend to normalization of tHcy levels in 5 of
15 hemodialysis patients by administration of 15 mg of folate, 100
mg of vitamin B6 and 1 mg of vitamin B12 in addition to a routine
vitamin treatment schedule [47]. However, in 10 of 15 patients
studied, Hcy concentrations did not return to normal values
raising the possibility of an influence of genetic determinants on
therapeutic efficacy in hyperhomocysteinemia.
In summary, our data provide evidence that severity of hyper-
homocysteinemia in hemodialysis patients is not only the result of
uremia, folate status and albumin levels, but is also genetically
determined. We found significanly higher tHcy levels in hemodi-
alysis patients with a homozygous 677 C to T MTHFR gene
mutation than in non-carriers. The allelic frequency of the 677 C
to T transition in a large cohort of Austrian hemodialysis patients
was similar to the allelic frequency in healthy subjects. Therefore,
the presence of the 677 C to T mutation in the MTHFR gene does
not appear to be a risk factor for development of end-stage renal
disease. Further studies are required to determine the prevalence
of vascular disease in patients with different MTHFR genotypes as
well as the impact of the MTHFR genotypes on treatment efficacy
of hyperhomocysteinemia in hemodialysis patients.
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